Data / Drug companies / Coupler LLC
Coupler LLC: 482 products in the FDA NDC directory, labeler code 67046
Coupler LLC (labeler code 67046) lists 482 products in the FDA National Drug Code Directory, covering 169 finished drugs by generic name. By type: 482 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on November 2, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 67046
- Products in commercial distribution
- 482
- Packages
- 482
- Finished drugs by generic name
- 169
- Prescription products
- 482
- Over the counter products
- 0
- Controlled substance products
- Schedule IV 23, Schedule V 4
- Started marketing in the last 12 months
- 308
- Products with a marketing end date set
- 3
- Earliest marketing start
- March 1, 2017
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 471 | 97.7% |
| Authorized generics (NDA) | 6 | 1.2% |
| Other unapproved drugs | 4 | 0.8% |
| New drug applications (NDA) | 1 | 0.2% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 482 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 232 | 48.1% |
| Tablet, film coated | 121 | 25.1% |
| Capsule | 62 | 12.9% |
| Tablet, extended release | 23 | 4.8% |
| Capsule, extended release | 11 | 2.3% |
| Tablet, coated | 10 | 2.1% |
| Tablet, delayed release | 8 | 1.7% |
| Tablet, film coated, extended release | 6 | 1.2% |
| Capsule, delayed release | 4 | 0.8% |
| Tablet, orally disintegrating | 2 | 0.4% |
| Tablet, sugar coated | 2 | 0.4% |
| Tablet, chewable | 1 | 0.2% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Lisinopril and Hydrochlorothiazide | 67046-0686 | Tablet | Generic drugs (ANDA) | November 2, 2026 |
| Venlafaxine Hydrochloride | 67046-0406 | Capsule, extended release | Generic drugs (ANDA) | November 2, 2026 |
| Azithromycin | 67046-1698 | Tablet, film coated | Generic drugs (ANDA) | October 28, 2026 |
| Fluconazole | 67046-2044 | Tablet | Generic drugs (ANDA) | October 26, 2026 |
| Fluconazole | 67046-0623 | Tablet | Generic drugs (ANDA) | October 26, 2026 |
| Fluoxetine | 67046-0405 | Capsule | Generic drugs (ANDA) | October 26, 2026 |
| Labetalol Hydrochloride | 67046-1697 | Tablet | Generic drugs (ANDA) | October 19, 2026 |
| Divalproex Sodium | 67046-0875 | Tablet, delayed release | Generic drugs (ANDA) | October 19, 2026 |
| Divalproex sodium | 67046-1696 | Tablet, film coated, extended release | Generic drugs (ANDA) | October 8, 2026 |
| PredniSONE | 67046-1294 | Tablet | Generic drugs (ANDA) | October 6, 2026 |
| Fluoxetine | 67046-1695 | Capsule | Generic drugs (ANDA) | October 2, 2026 |
| Amlodipine Besylate | 67046-1157 | Tablet | Generic drugs (ANDA) | September 8, 2026 |
| Olanzapine | 67046-0690 | Tablet, film coated | Generic drugs (ANDA) | September 8, 2026 |
| Warfarin Sodium | 67046-1145 | Tablet | Generic drugs (ANDA) | August 31, 2026 |
| Hydroxyzine hydrochloride | 67046-0566 | Tablet | Generic drugs (ANDA) | August 31, 2026 |
| Methocarbamol | 67046-0340 | Tablet, coated | Generic drugs (ANDA) | August 31, 2026 |
| Levofloxacin | 67046-1358 | Tablet, film coated | Generic drugs (ANDA) | August 26, 2026 |
| Enalapril Maleate | 67046-1254 | Tablet | Generic drugs (ANDA) | August 26, 2026 |
| Topiramate | 67046-0357 | Tablet, film coated | Generic drugs (ANDA) | August 26, 2026 |
| Amitriptyline Hydrochloride | 67046-1694 | Tablet, film coated | Generic drugs (ANDA) | August 21, 2026 |
| Warfarin Sodium | 67046-1185 | Tablet | Generic drugs (ANDA) | August 21, 2026 |
| Potassium Chloride | 67046-1032 | Tablet, film coated, extended release | Generic drugs (ANDA) | August 21, 2026 |
| Meclizine Hydrochloride | 67046-0869 | Tablet | Authorized generics (NDA) | August 21, 2026 |
| Paroxetine | 67046-0846 | Tablet, film coated | Generic drugs (ANDA) | August 21, 2026 |
| Amitriptyline Hydrochloride | 67046-0689 | Tablet, film coated | Generic drugs (ANDA) | August 21, 2026 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.